Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, August 25, 2022
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
[ Thu, Aug 25th 2022
] - WOPRAI
Wed, August 24, 2022
[ Wed, Aug 24th 2022
] - WOPRAI
[ Wed, Aug 24th 2022
] - WOPRAI
[ Wed, Aug 24th 2022
] - WOPRAI
Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $85 on, Aug 24th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $110 to $85 on, Aug 24th, 2022.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Graig Suvannavejh of "Mizuho" Initiated at Strong Buy and Held Target at $19 on, Thursday, July 7th, 2022
- Corinne Jenkins of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $10 on, Monday, May 9th, 2022
